Zhejiang Wolwo Bio-Pharmaceutical Co (SZSE:300357) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Zhejiang Wolwo Bio-Pharmaceutical Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Zhejiang Wolwo Bio-Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.00.

Zhejiang Wolwo Bio-Pharmaceutical Co's long-term debt to total assets ratio declined from Sep. 2023 (0.01) to Sep. 2024 (0.00). It may suggest that Zhejiang Wolwo Bio-Pharmaceutical Co is progressively becoming less dependent on debt to grow their business.

Zhejiang Wolwo Bio-Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Zhejiang Wolwo Bio-Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Wolwo Bio-Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Zhejiang Wolwo Bio-Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

Zhejiang Wolwo Bio-Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	-

Zhejiang Wolwo Bio-Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Zhejiang Wolwo Bio-Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	21.256	/	2562.167
	=	0.01

Zhejiang Wolwo Bio-Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	8.365	/	2701.045
	=	0.00

Zhejiang Wolwo Bio-Pharmaceutical Co (SZSE:300357) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Zhejiang Wolwo Bio-Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Zhejiang Wolwo Bio-Pharmaceutical Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhejiang Wolwo Bio-Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (SZSE:300357) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 636 Zhiyuan North Road, Wukang Town, Deqing County, Zhejiang Province, Huzhou, CHN, 313299

Website

http://www.wolwobiotech.com

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd is a Chinese bio-pharmaceutical company. It is engaged in the research development, production and sales of allergic diseases diagnosis and treatment products. The product portfolio of the company covers dust mites drops, dust mites skin prick diagnosis kit, silk, and others.

Executives

Hu Geng Xi	Directors, executives
Zhang Lu	Directors, executives
Wang Li Hong	Directors, executives
	Director
Li Qin	Supervisors
Wang Xin Hua	Secretary, Director
Li Xiao Nan	Supervisors

Zhejiang Wolwo Bio-Pharmaceutical Co Headlines

No Headlines